An interventional study of MRI in Breast Cancer, sponsored by University of Sao Paulo General Hospital. Completed at 1 site in Brazil. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Breast Neoplasms with a site in Brazil — 52 open to participants now, 111 under way, 62 of them phase 3. Breast Neoplasms · Brazil.
Among the 351 studies in Breast Neoplasms with a site in Brazil, this one is the 116th largest by enrollment of the 309 interventional ones that give a count, is one of 13 that started in 2014, is one of 78 with no phase, and was the 149th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →52 of the 351 studies in Breast Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:
BeOne Medicines · Sites in Brazil, United States, Australia and 13 more countries
Ages 18+
Hoffmann-La Roche · Sites in Brazil, United States, Argentina and 23 more countries
Ages 18+
Hoffmann-La Roche · Sites in Brazil, United States, Argentina and 9 more countries
Ages 18+
Eli Lilly and Company · Sites in Brazil, United States, Argentina and 16 more countries
Ages 18+
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18–65 · Women only
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 79 · Phase 3 150 · Phase 4 4
First in 1997; this study’s year is marked. 13 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 446 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 250 across the 309 interventional studies, 251 across the 40 observational. Of the 206 that completed or were terminated, 109 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 351 have an industry lead sponsor. The 10 most frequent:
University of Sao Paulo General Hospital is the lead sponsor of 612 studies on the registry; 99 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
University of Sao Paulo General Hospital has 5 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
31 of the studies in Breast Neoplasms with a site in Brazil that are under way reach primary completion within a year, 16 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT04906395Phase 3Tolmar Inc.Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | 2027-01-30 |
| NCT06839001Phase 3Hospital do CoracaoCRYoablation for Small Tumors As Local Treatment - SIX Trial | 2027-03-01 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT04540692Phase 3Latin American Cooperative Oncology GroupEvaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer | 2027-04 |
Add all 31 to your calendar (.ics) → With an account.
Among the 351 studies in Breast Neoplasms with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the ability of MRI to select patients for conservative treatment of breast cancer. Participants: female, over 18 years with breast cancer, stages I, II and III candidates for conservative surgery will be randomly randomized to do MRI or not according mammary density.
The aim of this study is to evaluate the ability of MRI to select patients for conservative treatment of breast cancer.An accurate assessment of the tumor is essential to select the best therapeutic strategy in the treatment of breast cancer.Currently, mammography, ultrasound and clinical examination are the standard techniques to assess the extent and location of the tumor.However, these imaging methods fail to assess the real size in approximately one third of patients eligible to conservative treatment.MRI has high sensitivity (95-100%) in the detection of invasive cancers as well as being able to detect hidden tumors, multifocality, multicentricity and cancer in the contralateral breast more often and greater accuracy than mammography or ultrasound.
The criteria were revised on the registry on Oct 23, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MRI Group - all patients will be submitted to clinical examination, mammography and / or ultrasound, and breast MRI
Device: MRI
Control group - all patients will be submitted to clinical examination, mammography and / or ultrasound of the breasts.
All patients will be submitted to MRI
local relapse-free survival
presence of local and regional relapse during the follow up time
Time frame: 5 years
overall survival between groups
Time frame: 5 years
disease free-survival between groups
Time frame: 5 years
Describe the percentage surgical change from conservative surgery to mastectomy
Time frame: 6 months
MRI findings in modifying the surgical management
The proportion of patients whose surgical approach was modified to mastectomy
Time frame: 6 months
reoperation rates
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2014 to primary completion in May 2025, 126 months.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 126 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Nov 2016 → May 2025 and completion Nov 2016 → May 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sao Paulo General Hospital →